Presentation AHA 2017 Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Presenter: Louise Bowman November 14, 2017 REGISTER for free or LOG IN to view this content Clinical Pharma Diabetes Presentation AHA 2017 Up Next Presentation AHA 2017 Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial Presenter: Andre Lamy November 15, 2017 More slides + Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017 Presentation AHA 2017 Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Presenter: Kenneth W. Mahaffey November 14, 2017 We Recommend
Presentation AHA 2017 Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial Presenter: Andre Lamy November 15, 2017
Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017
Presentation AHA 2017 Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Presenter: Kenneth W. Mahaffey November 14, 2017